Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$105.87 USD

105.87
498,510

-0.58 (-0.55%)

Updated Nov 11, 2024 12:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novartis' Asthma Treatment Meets Primary Endpoint in Phase III

by Zacks Equity Research

Novartis (NVS) announces positive results from a late-stage study on Enerzair Breezhaler in patients with asthma.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals

by Kinjel Shah

Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.

Novartis (NVS) Announces Positive Data From Cosentyx Study

by Zacks Equity Research

Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.

Novartis' sBLA for Ofatumumab Gets Extended Review From FDA

by Zacks Equity Research

The FDA stretches the review period for Novartis' (NVS) sBLA, seeking approval for ofatumumab to treat patients with relapsing multiple sclerosis. A new date in September 2020 is set for the decision.

AbbVie Seeks US and EU Nods for Rinvoq for Psoriatic Arthritis

by Zacks Equity Research

AbbVie (ABBV) files applications to the FDA and the EMA seeking approval for a new indication of Rinvoq, active psoriatic arthritis. The drug is already marketed to treat rheumatoid arthritis.

Novartis' (NVS) Breast Cancer Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) gets positive CHMP opinion for breast cancer drug, Piqray. The company also announces other pipeline updates.

Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study

by Zacks Equity Research

Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.

Zacks.com headshot

PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment

by Zacks.com

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

Alnylam's (ALNY) Lumasiran NDA Gets Priority Review From FDA

by Zacks Equity Research

Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.

Novartis Gets EC Approval for Gene Therapy Zolgensma in SMA

by Zacks Equity Research

Novartis' (NVS) gene therapy, Zolgensma, obtains EC approval for spinal muscular atrophy.

Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock

by Zacks Equity Research

The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.

Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Acceleron (XLRN) posts a wider-than-expected Q1 loss due to increased operating expenses. The company misses on revenues as well.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Puma Biotech's (PBYI) loss and revenues better estimates in the first quarter of 2020.

Bausch (BHC) Down on Q1 Earnings & Sales Miss, View Trimmed

by Zacks Equity Research

Bausch (BHC) misses on earnings and sales in the first quarter and lowers guidance due to the coronavirus pandemic.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

by Kinjel Shah

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Immunomedics (IMMU) Q1 Earnings Beat, Trodelvy in Focus

by Zacks Equity Research

Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.

Ligand (LGND) Beats on Q1 Earnings & Sales, Raises View

by Zacks Equity Research

Ligand (LGND) reports higher-than-expected first-quarter 2020 earnings and revenues.

Alnylam (ALNY) Beats on Q1 Earnings, Cuts Onpattro Sales View

by Zacks Equity Research

Alnylam (ALNY) loss narrows in Q1. It beats sales estimates but cuts guidance for product revenues from Onpattro due to potential impact of COVID-19.

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

by Zacks Equity Research

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.

Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.

Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates

by Zacks Equity Research

Regeneron (REGN) beats on Q1 earnings and sales on solid performance of ophthalmology drug, Eylea; asthma drug, Dupixent; and oncology drug, Libtayo.

Sheraz Mian headshot

Top Analyst Reports for Apple, Berkshire Hathaway & Pfizer

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Berkshire Hathaway (BRK.B) and Pfizer (PFE).

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

by Zacks Equity Research

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.